Insight Brief
FDA’s Rare Disease Evidence Principles (RDEP)
Use real world evidence in ultra-rare drug development
Jan 12, 2026
Download
This Insight Guide explores how the Rare Disease Evidence Principles (RDEP) process compares to existing pathways, in what situations it should be considered, and how sponsors can strategically leverage RWE and other evidence sources, as well as artificial intelligence (AI)-driven analytics, to prepare a successful submission.

Related solutions

Contact Us